JP2009531367A - 診断および治療のためのアデノシンおよびイノシンを組み合わせて使用する組成物、方法およびキット - Google Patents
診断および治療のためのアデノシンおよびイノシンを組み合わせて使用する組成物、方法およびキット Download PDFInfo
- Publication number
- JP2009531367A JP2009531367A JP2009501968A JP2009501968A JP2009531367A JP 2009531367 A JP2009531367 A JP 2009531367A JP 2009501968 A JP2009501968 A JP 2009501968A JP 2009501968 A JP2009501968 A JP 2009501968A JP 2009531367 A JP2009531367 A JP 2009531367A
- Authority
- JP
- Japan
- Prior art keywords
- adenosine
- inosine
- less
- pharmaceutical composition
- ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 title claims abstract description 1279
- 239000002126 C01EB10 - Adenosine Substances 0.000 title claims abstract description 639
- 229960005305 adenosine Drugs 0.000 title claims abstract description 639
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 title claims abstract description 357
- 229930010555 Inosine Natural products 0.000 title claims abstract description 357
- 229960003786 inosine Drugs 0.000 title claims abstract description 357
- 238000000034 method Methods 0.000 title claims abstract description 85
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- 238000003745 diagnosis Methods 0.000 title abstract description 5
- 238000011282 treatment Methods 0.000 title description 19
- 238000001802 infusion Methods 0.000 claims description 189
- 239000008194 pharmaceutical composition Substances 0.000 claims description 69
- 238000001990 intravenous administration Methods 0.000 claims description 40
- 230000006378 damage Effects 0.000 claims description 28
- 230000001154 acute effect Effects 0.000 claims description 26
- 230000000747 cardiac effect Effects 0.000 claims description 26
- 238000001356 surgical procedure Methods 0.000 claims description 26
- 238000012360 testing method Methods 0.000 claims description 26
- 208000014674 injury Diseases 0.000 claims description 25
- 208000027418 Wounds and injury Diseases 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 24
- 229940079593 drug Drugs 0.000 claims description 23
- 238000002347 injection Methods 0.000 claims description 20
- 239000007924 injection Substances 0.000 claims description 20
- 208000028867 ischemia Diseases 0.000 claims description 15
- 238000001361 intraarterial administration Methods 0.000 claims description 14
- 239000012530 fluid Substances 0.000 claims description 12
- 230000010412 perfusion Effects 0.000 claims description 11
- 230000009692 acute damage Effects 0.000 claims description 9
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 9
- 230000006872 improvement Effects 0.000 claims description 8
- 230000000302 ischemic effect Effects 0.000 claims description 8
- 238000002600 positron emission tomography Methods 0.000 claims description 8
- 208000010125 myocardial infarction Diseases 0.000 claims description 7
- 210000004351 coronary vessel Anatomy 0.000 claims description 6
- 230000004217 heart function Effects 0.000 claims description 6
- 206010052804 Drug tolerance Diseases 0.000 claims description 5
- 210000003169 central nervous system Anatomy 0.000 claims description 5
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 5
- 230000001698 pyrogenic effect Effects 0.000 claims description 5
- 238000002604 ultrasonography Methods 0.000 claims description 5
- 238000005481 NMR spectroscopy Methods 0.000 claims description 4
- 238000002583 angiography Methods 0.000 claims description 4
- 230000036593 pulmonary vascular resistance Effects 0.000 claims description 4
- 230000002537 thrombolytic effect Effects 0.000 claims description 4
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 3
- 210000000278 spinal cord Anatomy 0.000 claims description 3
- 208000035965 Postoperative Complications Diseases 0.000 claims description 2
- 238000002591 computed tomography Methods 0.000 claims description 2
- 238000011156 evaluation Methods 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000002592 echocardiography Methods 0.000 claims 1
- 230000003680 myocardial damage Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 115
- 230000009471 action Effects 0.000 abstract description 10
- 239000002777 nucleoside Substances 0.000 abstract description 10
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract description 5
- 238000002560 therapeutic procedure Methods 0.000 abstract description 5
- 230000004872 arterial blood pressure Effects 0.000 description 35
- 230000002792 vascular Effects 0.000 description 32
- 230000003247 decreasing effect Effects 0.000 description 24
- 230000001965 increasing effect Effects 0.000 description 23
- 230000002107 myocardial effect Effects 0.000 description 20
- 229940090044 injection Drugs 0.000 description 19
- 230000002861 ventricular Effects 0.000 description 18
- 230000036772 blood pressure Effects 0.000 description 17
- 230000017531 blood circulation Effects 0.000 description 16
- 241000700159 Rattus Species 0.000 description 15
- 238000011084 recovery Methods 0.000 description 14
- 230000008859 change Effects 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 230000007423 decrease Effects 0.000 description 10
- 238000007911 parenteral administration Methods 0.000 description 9
- 230000001681 protective effect Effects 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 208000036982 Spinal cord ischaemia Diseases 0.000 description 8
- 208000020431 spinal cord injury Diseases 0.000 description 8
- 206010063837 Reperfusion injury Diseases 0.000 description 7
- 230000002301 combined effect Effects 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 7
- 230000000004 hemodynamic effect Effects 0.000 description 7
- 239000004005 microsphere Substances 0.000 description 7
- 210000001147 pulmonary artery Anatomy 0.000 description 7
- 238000011552 rat model Methods 0.000 description 7
- 241001494479 Pecora Species 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 238000000540 analysis of variance Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 208000037906 ischaemic injury Diseases 0.000 description 6
- 230000010410 reperfusion Effects 0.000 description 6
- 230000024883 vasodilation Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000002173 dizziness Diseases 0.000 description 5
- 125000003835 nucleoside group Chemical group 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 230000001953 sensory effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 206010019233 Headaches Diseases 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000003205 diastolic effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 210000005240 left ventricle Anatomy 0.000 description 4
- 230000008338 local blood flow Effects 0.000 description 4
- 230000004089 microcirculation Effects 0.000 description 4
- 230000007659 motor function Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 210000005241 right ventricle Anatomy 0.000 description 4
- 230000035488 systolic blood pressure Effects 0.000 description 4
- 206010008469 Chest discomfort Diseases 0.000 description 3
- 206010016825 Flushing Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 208000001953 Hypotension Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 238000011260 co-administration Methods 0.000 description 3
- 230000008828 contractile function Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000036543 hypotension Effects 0.000 description 3
- 230000003601 intercostal effect Effects 0.000 description 3
- 210000004731 jugular vein Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 230000000324 neuroprotective effect Effects 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000001364 upper extremity Anatomy 0.000 description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 206010022680 Intestinal ischaemia Diseases 0.000 description 2
- 201000008450 Intracranial aneurysm Diseases 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 208000004535 Mesenteric Ischemia Diseases 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 206010033647 Pancreatitis acute Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 208000003734 Supraventricular Tachycardia Diseases 0.000 description 2
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 2
- 201000003229 acute pancreatitis Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000008321 arterial blood flow Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000007675 cardiac surgery Methods 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 210000001174 endocardium Anatomy 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 108700025647 major vault Proteins 0.000 description 2
- 208000037891 myocardial injury Diseases 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000250 revascularization Effects 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- IDELNEDBPWKHGK-UHFFFAOYSA-N thiobutabarbital Chemical compound CCC(C)C1(CC)C(=O)NC(=S)NC1=O IDELNEDBPWKHGK-UHFFFAOYSA-N 0.000 description 2
- 229960000103 thrombolytic agent Drugs 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 230000000304 vasodilatating effect Effects 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 102000009346 Adenosine receptors Human genes 0.000 description 1
- 108050000203 Adenosine receptors Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010058178 Aortic occlusion Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010052895 Coronary artery insufficiency Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010061224 Limb discomfort Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 239000002616 MRI contrast agent Substances 0.000 description 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- QJGQUHMNIGDVPM-BJUDXGSMSA-N Nitrogen-13 Chemical compound [13N] QJGQUHMNIGDVPM-BJUDXGSMSA-N 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004792 Prolene Substances 0.000 description 1
- 206010063897 Renal ischaemia Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000008166 Right Ventricular Dysfunction Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- IGLNJRXAVVLDKE-OIOBTWANSA-N Rubidium-82 Chemical compound [82Rb] IGLNJRXAVVLDKE-OIOBTWANSA-N 0.000 description 1
- 206010041549 Spinal cord compression Diseases 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- KRHYYFGTRYWZRS-BJUDXGSMSA-N ac1l2y5h Chemical compound [18FH] KRHYYFGTRYWZRS-BJUDXGSMSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960005054 acepromazine Drugs 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 229940060202 adenoscan Drugs 0.000 description 1
- 229940068274 adenosine injection Drugs 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000001042 autoregulative effect Effects 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- ZOXJGFHDIHLPTG-IGMARMGPSA-N boron-11 atom Chemical compound [11B] ZOXJGFHDIHLPTG-IGMARMGPSA-N 0.000 description 1
- OKTJSMMVPCPJKN-BJUDXGSMSA-N carbon-11 Chemical compound [11C] OKTJSMMVPCPJKN-BJUDXGSMSA-N 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 238000013172 carotid endarterectomy Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000002057 chronotropic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000002961 echo contrast media Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000002530 ischemic preconditioning effect Effects 0.000 description 1
- 229940039412 ketalar Drugs 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000002818 limb ischemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000002089 myocardial stunning Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000028412 nervous system injury Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000012346 open field test Methods 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- QVGXLLKOCUKJST-BJUDXGSMSA-N oxygen-15 atom Chemical compound [15O] QVGXLLKOCUKJST-BJUDXGSMSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000006552 photochemical reaction Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 239000002212 purine nucleoside Substances 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 239000003379 purinergic P1 receptor agonist Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000006814 right ventricular dysfunction Effects 0.000 description 1
- 210000000273 spinal nerve root Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 238000009662 stress testing Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229910052713 technetium Inorganic materials 0.000 description 1
- 229940056501 technetium 99m Drugs 0.000 description 1
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960004113 tetrofosmin Drugs 0.000 description 1
- QCWJONLQSHEGEJ-UHFFFAOYSA-N tetrofosmin Chemical compound CCOCCP(CCOCC)CCP(CCOCC)CCOCC QCWJONLQSHEGEJ-UHFFFAOYSA-N 0.000 description 1
- BKVIYDNLLOSFOA-OIOBTWANSA-N thallium-201 Chemical compound [201Tl] BKVIYDNLLOSFOA-OIOBTWANSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78777106P | 2006-03-31 | 2006-03-31 | |
| PCT/EP2007/002905 WO2007112986A1 (en) | 2006-03-31 | 2007-03-30 | Compositions, methods, and kits using adenosine and inosine in combination for diagnosis and treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009531367A true JP2009531367A (ja) | 2009-09-03 |
| JP2009531367A5 JP2009531367A5 (https=) | 2010-05-27 |
Family
ID=38197939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009501968A Withdrawn JP2009531367A (ja) | 2006-03-31 | 2007-03-30 | 診断および治療のためのアデノシンおよびイノシンを組み合わせて使用する組成物、方法およびキット |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080056993A1 (https=) |
| EP (1) | EP2004139A1 (https=) |
| JP (1) | JP2009531367A (https=) |
| KR (1) | KR20090010176A (https=) |
| CN (1) | CN101453984A (https=) |
| AU (1) | AU2007234006A1 (https=) |
| CA (1) | CA2647770A1 (https=) |
| IL (1) | IL194423A0 (https=) |
| NO (1) | NO20084599L (https=) |
| RU (1) | RU2008143202A (https=) |
| WO (1) | WO2007112986A1 (https=) |
| ZA (1) | ZA200808368B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2497489A1 (en) * | 2011-03-09 | 2012-09-12 | CSL Behring GmbH | Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs |
| HU227743B1 (en) | 2011-07-22 | 2012-02-28 | Debreceni Egyetem | Eardrop composition and process for producing this |
| CN105188750A (zh) | 2013-03-08 | 2015-12-23 | 德国杰特贝林生物制品有限公司 | 治疗和预防远端缺血-再灌注损伤 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5231086A (en) * | 1985-09-24 | 1993-07-27 | Item Development Aktiebolag | Continuous administration adenosine to increase myocardial blood flow |
| DE3701497A1 (de) * | 1987-01-20 | 1988-07-28 | Frankhof Wolfgang | Arzneimittel, enthaltend lokalanaesthetika und nukleoside sowie dessen verwendung zur behandlung von muskelverletzungen |
| US5070877A (en) * | 1988-08-11 | 1991-12-10 | Medco Research, Inc. | Novel method of myocardial imaging |
| US5187162A (en) * | 1989-09-15 | 1993-02-16 | Gensia Pharmaceuticals | Methods of treating neurodegenerative conditions |
| US6180616B1 (en) * | 1990-05-10 | 2001-01-30 | Atsuo F. Fukunaga | Use of purine receptor agonists to alleviate or normalize physiopathologically excited sensory nerve function |
| US6004945A (en) * | 1990-05-10 | 1999-12-21 | Fukunaga; Atsuo F. | Use of adenosine compounds to relieve pain |
| US5677290A (en) * | 1990-05-10 | 1997-10-14 | Fukunaga; Atsuo F. | Therapeutic use of adenosine compounds as surgical anesthetics |
| US5236908A (en) * | 1991-06-07 | 1993-08-17 | Gensia Pharmaceuticals, Inc. | Methods of treating injury to the central nervous system |
| US5443836A (en) * | 1993-03-15 | 1995-08-22 | Gensia, Inc. | Methods for protecting tissues and organs from ischemic damage |
| WO1994023723A1 (en) * | 1993-04-15 | 1994-10-27 | New York University | Adenosine receptor agonists for the promotion of wound healing |
| SE9301324D0 (sv) * | 1993-04-21 | 1993-04-21 | Item Development Ab | New method of treatment |
| US6342484B1 (en) * | 1993-06-30 | 2002-01-29 | Board Of Regents, The University Of Texas Systems | Method and compositions for promotion of wound treatment |
| US5852000A (en) * | 1993-08-25 | 1998-12-22 | Otsuka Pharmaceutical Factory, Inc. | Cardiac rehabilitation agent |
| US5646156A (en) * | 1994-04-25 | 1997-07-08 | Merck & Co., Inc. | Inhibition of eosinophil activation through A3 adenosine receptor antagonism |
| SE9401499D0 (sv) * | 1994-05-02 | 1994-05-02 | Item Dev Ab | New method of treatment |
| US5629298A (en) * | 1995-03-13 | 1997-05-13 | University Of Massachusetts Medical Center | Adenosine as a positive inotrop in the compromised heart |
| US5733916A (en) * | 1995-03-24 | 1998-03-31 | The Trustees Of The University Of Pennsylvania | Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists |
| US5801159A (en) * | 1996-02-23 | 1998-09-01 | Galileo Laboratories, Inc. | Method and composition for inhibiting cellular irreversible changes due to stress |
| AU2603197A (en) * | 1996-04-10 | 1997-10-29 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Use of an a1 adenosine receptor agonist to treat cerebral ischaemia |
| US5873366A (en) * | 1996-11-07 | 1999-02-23 | Chim; Nicholas | Method for transmyocardial revascularization |
| US6211165B1 (en) * | 1997-05-09 | 2001-04-03 | The Trustees Of The University Of Pennsylvania | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
| US6432986B2 (en) * | 1997-07-21 | 2002-08-13 | Bruce H. Levin | Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches |
| US6440455B1 (en) * | 1997-09-02 | 2002-08-27 | Children's Medical Center Corporation | Methods for modulating the axonal outgrowth of central nervous system neurons |
| US5998386A (en) * | 1997-09-19 | 1999-12-07 | Feldman; Arthur M. | Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue |
| AU1363699A (en) * | 1997-10-23 | 1999-05-10 | National Institute Of Health | Methods for reducing ischemic injury of the heart via the sequential administ ration of monophosphoryl lipid a and adenosine receptor agents |
| US6958324B2 (en) * | 1998-12-02 | 2005-10-25 | Inotek Pharmaceuticals Corporation | Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease |
| EP1168912B1 (en) * | 1999-03-23 | 2007-05-09 | Hibernation Therapeutics Limited | Organ arrest, protection and preservation |
| US6103702A (en) * | 1999-05-24 | 2000-08-15 | Board Of Trustees Of The University Of Illinois | Use of adenosine deaminase inhibitors to treat systemic inflammatory response syndrome |
| US6586413B2 (en) * | 1999-11-05 | 2003-07-01 | The United States Of America As Represented By The Department Of Health And Human Services | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
| US6492103B1 (en) * | 2000-01-31 | 2002-12-10 | Organ Recovery Systems, Inc. | System for organ and tissue preservation and hypothermic blood substitution |
| US6566371B2 (en) * | 2000-04-28 | 2003-05-20 | University Of Pittsburgh | Intraperitoneal administration of adenosine for the treatment of prevention of gastrointestinal of systemic diseases |
| US6599283B1 (en) * | 2001-05-04 | 2003-07-29 | Cv Therapeutics, Inc. | Method of preventing reperfusion injury |
| EP1575562B1 (en) * | 2002-11-26 | 2016-10-05 | Seacoast Neurosciene, Inc. | Buoyant polymer particles delivering therapeutic agents |
-
2007
- 2007-03-30 WO PCT/EP2007/002905 patent/WO2007112986A1/en not_active Ceased
- 2007-03-30 CN CNA2007800200114A patent/CN101453984A/zh active Pending
- 2007-03-30 AU AU2007234006A patent/AU2007234006A1/en not_active Abandoned
- 2007-03-30 ZA ZA200808368A patent/ZA200808368B/xx unknown
- 2007-03-30 EP EP07723846A patent/EP2004139A1/en not_active Withdrawn
- 2007-03-30 JP JP2009501968A patent/JP2009531367A/ja not_active Withdrawn
- 2007-03-30 US US11/693,967 patent/US20080056993A1/en not_active Abandoned
- 2007-03-30 KR KR1020087026487A patent/KR20090010176A/ko not_active Withdrawn
- 2007-03-30 CA CA002647770A patent/CA2647770A1/en not_active Abandoned
- 2007-03-30 RU RU2008143202/15A patent/RU2008143202A/ru not_active Application Discontinuation
-
2008
- 2008-09-28 IL IL194423A patent/IL194423A0/en unknown
- 2008-10-30 NO NO20084599A patent/NO20084599L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL194423A0 (en) | 2009-08-03 |
| CN101453984A (zh) | 2009-06-10 |
| KR20090010176A (ko) | 2009-01-29 |
| US20080056993A1 (en) | 2008-03-06 |
| CA2647770A1 (en) | 2007-10-11 |
| ZA200808368B (en) | 2009-12-30 |
| NO20084599L (no) | 2008-10-30 |
| EP2004139A1 (en) | 2008-12-24 |
| AU2007234006A1 (en) | 2007-10-11 |
| WO2007112986A1 (en) | 2007-10-11 |
| RU2008143202A (ru) | 2010-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hughes et al. | Therapeutic angiogenesis in chronically ischemic porcine myocardium: comparative effects of bFGF and VEGF | |
| JP6858716B2 (ja) | 心筋ミオシン活性化剤と洞房結節Ｉｆ電流阻害剤の併用療法 | |
| JP2000507954A (ja) | 心拍停止の処置のためのバソプレシン及びアドレナリン作用薬の組合せ | |
| Redfors et al. | Cardioprotective effects of isoflurane in a rat model of stress-induced cardiomyopathy (takotsubo) | |
| KR20070095925A (ko) | 천식이나 기관지 경련의 병력이 있는 환자에게서 심근기능장애를 검출하는 방법 | |
| Mychaliska et al. | Safety and efficacy of perflubron-induced lung growth in neonates with congenital diaphragmatic hernia: Results of a prospective randomized trial | |
| JP5947316B2 (ja) | 肺高血圧症を処置するための方法 | |
| JP2009531367A (ja) | 診断および治療のためのアデノシンおよびイノシンを組み合わせて使用する組成物、方法およびキット | |
| US20060167021A1 (en) | Inhibition of src for treatment of reperfusion injury related to revascularization | |
| Hing et al. | Combining cariporide with glyceryl trinitrate optimizes cardiac preservation during porcine heart transplantation | |
| Salgado-Garcia et al. | Safety of regadenoson in patients with severe chronic obstructive pulmonary disease | |
| JP2007517915A (ja) | 麻酔からの回復のためのリボースの使用方法 | |
| Golzar et al. | Nuclear Cardiology Bullets-Chest pain and ST-segment elevation 3 minutes after completion of adenosine pharmacologic stress testing | |
| Wenzel et al. | Effects of intravenous arginine vasopressin on epicardial coronary artery cross sectional area in a swine resuscitation model | |
| KR20090027258A (ko) | 부작용이 감소된 약리학적 스트레스 시험 방법, 조성물, 단위 투여형, 및 키트 | |
| Vlietstra et al. | Effect of verapamil on left ventricular function: a randomized, placebo-controlled study | |
| JP2025513337A5 (https=) | ||
| BR112015009291B1 (pt) | uso de clevidipina para controle da pressão arterial e redução da dispneia na insuficiência cardíaca | |
| Smith | Management of chronic degenerative mitral valve disease in dogs | |
| Yavuz et al. | Role of endogenous adenosine in atrial fibrillation after coronary artery bypass graft | |
| JP2015520142A (ja) | 非経口エスモロール製剤 | |
| Osborn | Adenosine for transient cardiac standstill in neurovascular surgery: A heart-stopping moment | |
| RU2299730C1 (ru) | Способ лечения острого инфаркта миокарда | |
| WO2025128432A1 (en) | Istaroxime and metabolite derivatives thereof for reducing the risk of acute myocardial arrhythmia | |
| US20080070917A1 (en) | Methods for administering levosimendan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100330 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100330 |
|
| A072 | Dismissal of procedure [no reply to invitation to correct request for examination] |
Free format text: JAPANESE INTERMEDIATE CODE: A073 Effective date: 20110729 |
|
| A300 | Application deemed to be withdrawn because no request for examination was validly filed |
Free format text: JAPANESE INTERMEDIATE CODE: A300 Effective date: 20110802 |